GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Up 142.8% in June

GeoVax Labs, Inc. (NASDAQ:GOVX) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 109,000 shares, an increase of 142.8% from the May 31st total of 44,900 shares. Currently, 4.4% of the company’s shares are short sold. Based on an average daily volume of 1,060,000 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC acquired a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned 91.38% of GeoVax Labs as of its most recent SEC filing. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Stock Down 10.3 %

GeoVax Labs stock traded down $0.36 during mid-day trading on Friday, hitting $3.19. 19,815,805 shares of the stock were exchanged, compared to its average volume of 7,368,152. The firm’s fifty day simple moving average is $1.76 and its two-hundred day simple moving average is $2.72. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $10.24.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Tuesday, May 14th. The company reported ($2.47) earnings per share (EPS) for the quarter. Equities analysts predict that GeoVax Labs will post -7.41 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright increased their price target on GeoVax Labs from $8.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, June 18th.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.